Prothena Corporation plc provided financial guidance for the full year 2020. For the period, the company expects an estimated net loss of $84 million to $106 million, which includes an estimated $23 million of non-cash shared-based compensation expense.

The company also announced that the Phase 2 PASADENA study in patients with early Parkinson's disease (N=316) is being conducted by Roche, and data from Part 1 of this study are expected to be reported in 2020. Additional data from the dose-escalation and long-term extension portions of the study of PRX004 are expected to be reported in 2020. The preclinical tau program, part of a global neuroscience collaboration with Bristol-Myers Squibb, is expected to advance IND-enabling activities in 2020. The preclinical Aß program is expected to initiate IND-enabling studies in 2020.